Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results
Portfolio Pulse from
Elanco Animal Health reported its Q4 2024 financial results with a slight revenue decrease of 1% on a reported basis but a 4% increase on an organic constant currency basis. The company faced a reported net loss of $8 million but achieved an adjusted net income of $72 million. Adjusted EBITDA was $177 million, with a reported EPS of $(0.02) and an adjusted EPS of $0.14, despite a $7 million FX headwind.
February 25, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Elanco Animal Health's Q4 2024 results show a slight revenue decrease on a reported basis but growth on an organic constant currency basis. The company reported a net loss but achieved a positive adjusted net income and EPS, despite FX headwinds.
The financial results indicate mixed performance with a reported net loss but positive adjusted earnings. The FX headwind impacted results, but the organic growth and adjusted EPS are positive signs. The stock price impact is likely neutral as the market may have anticipated these results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100